Newron announces US initiation of its ENIGMA-TRS 2 Phase III global study of evenamide for patients with treatment-resistant ...
Zacks Investment Research on MSN
Why TriMas (TRS) is a top growth stock for the long term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
TriMas Corporation’s TRS performance continues to be dragged down by the lackluster performance of its packaging segment. The segment’s top-line growth has been in the negative territory over the past ...
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback